Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904957 | 1.00 | PLA2G7 (0.52) | PLA2G7FFAR4 | |
| SCHEMBL15904960 | 1.00 | PLA2G7 (0.52) | PLA2G7FFAR4 | |
| SCHEMBL15904764 | 0.91 | PLA2G7 (0.50) | PLA2G7FFAR4 | |
| SCHEMBL15905095 | 0.91 | PLA2G7 (0.50) | PLA2G7FFAR4 | |
| SCHEMBL15904761 | 0.91 | PLA2G7 (0.50) | PLA2G7FFAR4 | |
| SCHEMBL15904891 | 0.90 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15904749 | 0.90 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15904746 | 0.90 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15904977 | 0.89 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15905398 | 0.89 | PLA2G7 (0.49) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| EP-2948456-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | PLA2G4A, PLA2G7, PLA2G6 | PLA2G7 2/4885FFAR4 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.